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Treatment of multidrug-resistant
Pseudomonas aeruginosa infections: more
attention required to in-vitro studies
We read with great interest the article in Clinical
Microbiology and Infection by Rossolini and Mant-
engoli [1], in which they presented a review of the
treatment of severe infections caused by multi-
drug-resistant Pseudomonas aeruginosa (MDRPA).
As mentioned in their article, therapeutic choices
are usually based on expert recommendations,
and clinical data supporting a particular thera-
peutic approach are limited. For example, the
indications for the use of combination therapy, as
opposed to monotherapy, for the treatment of
severe infections continue to be an issue for
debate [1]. The best information comes from
recently published meta-analyses, although the
results of these remain controversial [2,3].
The absence of clinical studies regarding ther-
apy for MDRPA infections is a cause for concern,
considering the increasing worldwide prevalence
of these infections [1]. In many cases, the only
agents remaining effective for the treatment of
these infections are polymyxin B or E (colistin).
Nevertheless, therapy with polymyxins clearly
has several limitations: (1) the response is vari-
able, with in-hospital mortality rates between
18% and 61% according to published series, and
even poorer outcomes for patients with pneu-
monia, perhaps because of the low levels
achieved by these drugs in lung tissue [4–6]; (2)
signiﬁcant nephrotoxicity; (3) the lack of stand-
ardisation of disk-diffusion tests for assessing
susceptibility in clinical practice [1]; and (4) the
inevitable emergence of resistance following the
widespread use of these agents.
Although there is an urgent need for new
drugs, this need seems unlikely to be met in the
near future [7]. Thus, the threat that many of
these infections will become untreatable has
encouraged many researchers to search for alter-
native therapeutic strategies against MDRPA.
Promising alternatives emerging from in-vitro
studies include: the use of double or triple
antibiotic combinations that aim to provide a
synergic bactericidal or post-antibiotic effect
[8,9]; the combination of rifampicin with cur-
rently used anti-pseudomonal drugs [10]; the use
of b-lactams administered by continuous infu-
sion in order to potentiate or rescue the activity
of these agents against resistant strains by the
optimisation of their pharmacodynamic parame-
ters [11]; and the use of macrolides as adjuvant
agents by exploiting their immunomodulatory
effects or actions on bioﬁlms formed by
P. aeruginosa [12,13].
Although publications describing these prom-
ising in-vitro approaches appear increasingly in
the scientiﬁc literature, there is an absence of
clinical studies evaluating such therapeutic
options for the treatment of MDRPA infections.
Thus, the evidence in support of prescribing
potentially beneﬁcial non-conventional treatment
options is lacking. Although it is unlikely to be
possible to design randomised clinical trials [7], it
seems reasonable that many of these potentially
beneﬁcial, and probably harmless, treatments
should be tried in clinical practice. Since the
emergence of MDRPA brings us closer to the
much-feared ‘end of antibiotics’ [7], it does not
seem wise to ignore promising in-vitro and
experimental ﬁndings. It is time to carefully
consider these ﬁndings and test them in small
clinical trials. Considering the unlikelihood of
randomised trials, clinical data for or against the
use of alternative treatments for MDRPA infec-
tions might come from cumulative case series or
small trials.
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Lymphopenia in hospitalised cases of
leptospirosis
The article published in Clinical Microbiology and
Infection by Jaure´guiberry et al. [1] presented an
interesting description of the clinical ﬁndings for
34 patients hospitalised with leptospirosis in a
hospital from the Pontchaillou area of France. The
most striking ﬁnding was the high frequency of
lymphopenia (< 1000 lymphocytes ⁄mm3), which
was observed for 85% of the leptospirosis patients
analysed. By performing a MedLine search, we
veriﬁed that this ﬁnding had not been reported
previously in the literature. Jaure´guiberry et al.
raised the possibility that this high frequency
of lymphopenia could be speciﬁc to leptospirosis
in the Pontchaillou area, but more deﬁnite
conclusions could not be drawn because of a
lack of published studies from other regions in
which this issue was addressed. In response, we
re-analysed our data for 253 leptospirosis patients
enrolled in a clinical trial [2] conducted in an
infectious disease hospital in the city of Salvador,
Brazil. The percentage of patients (17%) with
lymphocyte counts < 1000 ⁄mm3 at admission was
much lower than the ﬁgure (85%) reported by
Jaure´guiberry et al. Interestingly, our patients
with lymphopenia had a signiﬁcantly lower mean
platelet count than patients with higher leukocyte
counts (133 089 ± 55 203 ⁄mm3 vs. 162 626 ± 95
956 ⁄mm3; p 0.014).
As the frequency of icteric patients was much
higher in our study than in the Pontchaillou study
(94.1% vs. 34.3%), we also assessed whether this
ﬁnding could explain the difference in lymphope-
nia between the studies. However, no signiﬁcant
difference (p 0.910) was observed between the
mean lymphocyte counts of patients with
(2196 ± 1384 ⁄mm3) and without jaundice
(2226 ± 1469 ⁄mm3).
It should be noted that, while the serovar
Copenhageni has been the most frequent serovar
isolated from patients hospitalised in Salvador,
the serovar Grippotyphosa was the serovar
isolated most frequently in the Pontchaillou
hospital [1,3]. Interactions between host immune
response and environmental factors, including
the distribution of serovars, may provide expla-
nations for the differences in the frequency of
lymphopenia between patients hospitalised in
Salvador and those hospitalised in the Pontchail-
lou area of France. The correlation between
lymphocyte and platelet counts suggests that
there are similarities in the factors that mediate
the development of lymphopenia and plaque-
topenia in leptospirosis patients. The prevalence
of lymphopenia in patients with leptospirosis
across regions, and the factors related to any
variations, are important questions for future
research.
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